Zuellig Pharma

Zuellig Pharma had the privilege of leading a Product Identification Training session for members of the ASEAN Customs Enforcement and Compliance Working Group in Kuching, Malaysia, last month. Jointly organised by the EU-ASEAN Business Council, Royal Malaysian Customs Department and The ASEAN Secretariat, the event aimed to provide a valuable platform for key industry players to discuss ways to ensure product integrity through improved traceability and transparency across the supply chain.   Zuellig Pharma's Regional Government Affairs Lead Ling Di Koh gave an insightful presentation on the challenges faced by the ASEAN healthcare industry in dealing with counterfeits, emphasising the importance of strengthening track-and-trace systems and consumer awareness campaigns to effectively address this growing issue of illicit medicines.   Through various case studies, she illustrated how eZTracker, Zuellig Pharma's blockchain-powered end-to-end supply chain traceability solution promotes security, compliance and trust across the ecosystem to improve patient safety and assurance.   At Zuellig Pharma, we are committed to collaborating with government agencies, international and regional bodies, and industry players to drive transformative change for pressing issues in the sector, as we make healthcare more accessible for the communities we serve.   #MakingHealthcareMoreAccessible #eZTracker #Traceability #TrackAndTrace #ProductIntegrity

The Zuellig Pharma team in Thailand held their annual Team Engagement Meeting at SO Sofitel Hua Hin, Thailand, uniting 80 people managers from across the business for three transformative days of learning and bonding. The retreat featured various segments to facilitate strategic alignment with organisational priorities—from management presentations providing key updates on the business to curated workshops aimed at enhancing skills in digital literacy and stress management. Complementing these sessions were team bonding and wellness activities, such as yoga, tai chi and water aerobics, true to our holistic approach towards boosting employee engagement and collaboration. Zuellig Pharma recognises that people are our greatest asset and remains committed to fostering a positive work culture that supports continuous learning and team synergies. #ZuelligPharmaThailand #MakingHealthcareMoreAccessible #TeamBonding #EmployeeEngagement

With carbon emissions from the healthcare industry accounting for 30% of Asia’s gross emissions, more needs to be done to minimise environmental impact—especially in light of Asia’s ageing population and increasing climate risks jeopardising health.   In a recent interview with Eco-Business, Zuellig Pharma CEO John A. Graham shared his insights on the impact of climate change on the health of societies, the decarbonisation challenges faced within the sector, and how Zuellig Pharma has rolled out initiatives to reduce emissions and waste as a leading healthcare solutions company in Asia.   View the full article here: https://lnkd.in/gHgEuFxR   Read our 2023 Sustainability Report to learn more about our commitment to sustainability: https://lnkd.in/g7beNQ3A   #MakingHealthcareMoreAccessible #Sustainability #CarbonEmissions #WasteManagement #Decarbonisation

Zuellig Pharma is pleased to announce an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in South Korea and Taiwan. Regeneron is a leading biotechnology company that invents, develops and commercialises life-transforming medicines for people with serious diseases. Libtayo® (cemiplimab) is currently approved for first-line monotherapy treatment of advanced non-small cell lung cancer (NSCLC), the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and recurrent or metastatic cervical cancer in Korea. It is approved for monotherapy treatment of advanced NSCLC in Taiwan. “We are excited to accelerate the availability of Libtayo® to patients in South Korea and Taiwan. With our proven track record and deep understanding of the complex biopharma environment in Asia, we are uniquely positioned to deliver innovative therapies to patients in the region. This also represents a significant milestone in our mission to make healthcare more accessible and improve patient outcomes, especially in the burgeoning oncology segment,” said CEO of Zuellig Pharma, John A. Graham. Libtayo®, which was invented using Regeneron's proprietary VelocImmune® technology, is currently approved by regulatory authorities in more than two dozen countries for various indications. Read the press release here: https://lnkd.in/gZcX3xrr #ZuelligPharma #ZPTherapeutics #HealthcareCommercialization #Oncology #MakingHealthcareMoreAccessible

Zuellig Pharma is thrilled to share that our Thailand business has recently received two awards—the GIP Plus Award 2024 from the Food & Drug Administration (FDA) in Thailand and the Moral Health Learning Centre for the Year 2024 Award conferred by the Centre for Morality Promotion and Thai Health Promotion Foundation . Presented during the FDA's event "Promoting Entrepreneurs to Import Health Products According to Good Importing Practices (GIP) for Health Products" on 30 July, the GIP Plus Award 2024 recognises our unwavering commitment to elevating our standards of healthcare product importation and consistently delivering the highest levels of excellence in quality, safety, and compliance for our valued clients and customers. The Moral Health Learning Centre for the Year 2024 Award, which was announced during the “Moral Business Forum 2024: Sustainable Well-Being with Empowerment” event on 16 August, is Zuellig Pharma Thailand's second consecutive win. The award underscores our critical role as a leading hub for ethical health learning and reaffirms our steadfast dedication to sustainable development and ethical business practices. Congratulations to the Zuellig Pharma Thailand team on these accolades! #ZuelligPharmaThailand #FDA #GoodImportingPractices #EthicalBusiness #Quality #Awards

Zuellig Pharma’s holding company Interpharma Investments Limited (IIL) is pleased to announce the appointment of Dr. Christiane Hamacher as a new member of its Board of Directors.   Dr. Hamacher joins the board with over two decades of experience in the pharmaceutical and biotech industries. She has served in numerous leadership roles across the value chain, advising Boards and management teams of various industry-leading organisations on issues related to developing future-oriented business models, global strategic portfolio planning and organisation transformation.   The Board looks forward to working closely with Dr. Hamacher as it continues to focus on its mission of making healthcare more accessible in Asia.   Read the full announcement here: https://lnkd.in/gUEi9PYs   #ZuelligPharma #MakingHealthcareMoreAccessible #BoardAppointment

Zuellig Pharma was pleased to be a part of the Taiwan Clinical Research Association's 2024 Good Manufacturing Practice (GMP) Training Workshop last month, which brought together representatives from over 50 organisations consisting of Contract Research Organisations (CROs) and global biotech and pharmaceutical companies.   Quality Assurance Manager Sandra Wang facilitated a session on GMP and Good Distribution Practice (GDP), highlighting Zuellig Pharma's innovative and robust processes in accordance with the latest global standards, while shedding light on critical areas involving Investigational Medicinal Products (IMP), secondary packaging and labelling, cold chain management, returns and destruction. She also elaborated on how Zuellig Pharma ensures that the products we deliver meet the highest standards of quality assurance, to maintain product integrity and mitigate risks across the clinical trial supply chain.   As Decentralised Clinical Trials (DCT) gain significant attention in recent years, Senior Operations and Project Manager Tracy Chui shared valuable insights on adopting DCT guidelines and the Direct-to-Patient (DTP) model, which enables the delivery of IMP direct to patients’ homes. She provided a compelling case on how our DTP services can provide benefits for patients, sponsors and sites, ultimately improving patient participation and retention rates in clinical trials.   At Zuellig Pharma, we specialise in providing tailored solutions to meet the unique clinical sourcing and supply chain requirements of our clients, ensuring efficiency and accountability at every step. Learn more about our Clinical Reach solutions here: https://lnkd.in/gVNk4ra   #ZuelligPharmaClinicalReach #ZuelligPharmaTaiwan #DecentralizedClinicalTrials #GoodManufacturingPractice

Last month, Zuellig Pharma ESG Leads from across the region gathered in Kuala Lumpur, Malaysia, for our inaugural Sustainability Workshop, aimed at providing a platform to review our environmental, social, and governance (ESG) progress, reflect on best practices, and chart the course for our future. The workshop featured an array of engaging formats—including thought-provoking panel discussions, intimate fireside chats, and interactive training sessions—led by Zuellig Pharma leaders, esteemed clients, and renowned sustainability experts. From explorations of the latest trends in sustainability and ESG, to dialogues on labour practices and human rights, the sessions highlighted the importance of stakeholder partnerships and collaboration in driving meaningful change throughout our supply chain. The workshop also saw a strong emphasis on diversity, equity, and inclusion (DEI), with engaging action-planning activities designed to strengthen an inclusive workplace culture. Last but not least, the attendees had the privilege of visiting our Zuellig Pharma Malaysia Distribution Centre warehouse, where they witnessed firsthand the latest innovative green initiatives that were implemented to reduce our environmental footprint. As an industry leader in Sustainability, Zuellig Pharma will continue to collaborate with our stakeholders and champion sustainability efforts, as we focus on building a healthier future for Asia. #Sustainability #ESG #SustainabilityatZP #BuildingAHealthierFutureForAsia

Zuellig Pharma is pleased to announce our commercialisation partnership with Novartis Singapore to expand access of their strategic portfolio of In-Market Brands (IMB) in Singapore. This partnership brings together the expertise of Zuellig Pharma Singapore and Novartis Singapore to enhance patients’ access to cutting-edge medicines within our local communities. Under this exclusive agreement, Zuellig Pharma Singapore will leverage our deep-rooted expertise and proven track record in the healthcare market in Asia, to serve as Novartis Singapore’s dedicated commercialisation and distribution partner across medical oncology, neuroscience and general medicine. As part of this expanded partnership, ZP Therapeutics, a division of Zuellig Pharma, will spearhead the sales and marketing activities for Novartis Singapore’s IMB portfolio in Singapore. “Zuellig Pharma’s partnership with Novartis, via ZP Therapeutics, marks a significant milestone, ensuring the availability of various specialty and general medicines in Singapore. With our extensive expertise in healthcare commercialisation, we are committed to delivering vital support to doctors and allied healthcare professionals, particularly in medical oncology, neuroscience and general medicine”, said Binh Thai, General Manager of ZP Therapeutics Singapore, Malaysia and Brunei. “At Novartis, we are committed to ensuring that our medicines are accessible to as many patients as possible. This strategic partnership with Zuellig Pharma Singapore allows us to harness their extensive partner network and commercial expertise, strengthening our distribution network and improving access to our products to meet Singapore’s dynamic healthcare needs”, said Hwee Tee Poh, Country President, Singapore & Asian and Emerging Markets, Novartis Singapore. Tan Yan Ann Seong Fui Foo #ZPTherapeutics #ZuelligPharmaSingapore #HealthcareAccess #HealthcareCommercialisation #Partnership

The Zuellig Pharma team in the Philippines concluded their One PH Leadership Summit last month, bringing together leaders from across various business units and functions in the market. Themed "Passion to Lead," the Summit provided a platform for our leaders to exchange insights, strategies, and personal stories as they remain focused on our overarching mission of making healthcare more accessible.   The Summit kicked off with opening remarks by Market Managing Director Jannette Jakosalem, who emphasised Zuellig Pharma's strategic direction and the importance of setting clear and achievable objectives to produce results that will allow us to invest in our people. She was then joined by General Managers Freek Meerhoff and Ninia Torres for a fireside chat facilitated by HR Head Dan Oira, as they expounded on the important role each team plays in achieving our organisational vision and strategy.   This was followed by insightful sessions by two external speakers, designed to inspire our leaders to embrace change and challenge the status quo. Renowned business speaker Francis Kong shared uplifting stories on how adopting a winning mindset can enable organisations to stay ahead of the fiercest competition, while Chief Technology and Operations Officer of GCash Pebbles Sy talked about GCash’s digital transformation journey enabled by their vision and passion for financial inclusion.   To end the Summit, the leaders were encouraged to reflect on successes and areas of improvement before penning down their commitments on a Commitment Wall—representing their dedication to continue to lead with passion and take Zuellig Pharma to the next level.   #ZuelligPharmaPhilippines #Leadership #MakingHealthcareMoreAccessible